Global sales of blood testing reached $ 2,285 million in 2012 according to Kalorama’s new report.
New York, NY (PRWEB) June 11, 2013
Driven by the use of molecular tests and inelastic pricing for them, the blood testing market is expected to grow in double-digits according to Kalorama Information. The healthcare market research publisher said the need to provide the lowest level of blood contaminants is driving sales of newer nucleic acid tests that are replacing immunoassay units. Global sales of blood testing reached $ 2,285 million in 2012 according to Kalorama’s new report, “Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products.”
Unlike many other medical equipment markets, the company says unusual characteristic of the markets for blood bank testing technology is that, particularly in the developed nations, they immediately embrace new approaches that are declared the standard for blood safety. This is due to the requirement, both stated and implied, that blood and plasma collection facilities use the most up-to-date technology to ensure the safety of the blood supply.
“The market for blood banking and plasmapheresis testing reagents is inelastic, you might say locked,” said Bruce Carlson, Publisher of Kalorama Information. “Blood banks must use the latest technology and reagents, and with limited competition, companies have considerable discretion over pricing.”
Volume buys also make it more difficult for price reductions to occur, according to Kalorama. Blood banks and plasmapheresis centers also cannot effectively “cherry pick” their reagents from various molecular diagnostics suppliers, even as new competition appears. Pricing and discounting for reagents and supplies is generally based on total volume, therefore attempts to spread the business around could actually leave the blood bank or plasmapheresis center with less than optimal pricing overall.
Immunoassays for HIV, hepatitis B, hepatitis C and syphilis have been the routine approach to testing blood units for blood borne infectious agents. The 2012 market for blood screening immunoassays performed by blood public, private and hospital-based transfusion services is expected to grow slowly, while nucleic acid testing (NAT) has allowed blood banks to detect viral contamination, including West Nile Virus, HIV and hepatitis C, sooner and prevent them from slipping into blood transfusions, and has now become an integral part of the concerted effort to make blood transfusions safer. Due to their lower cost, immunoassays and/or in-lab developed PCR tests tend to be utilized more frequently in the developing nations while nucleic acid testing is used predominantly in the developed countries, although this is changing.
Due to the significant technological barriers to entry, the market for immunoassay blood testing products is dominated by a handful of companies. Outside of Asia, the market for immunoassay blood screening is controlled by two companies—Abbott Laboratories and Ortho Clinical Diagnostics. Abbott and Ortho hold most of the market, but Bio-Rad/Sanofi/Genetic Systems, Diasorin and bioMérieux are also competitive in the area.
The report “Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products,” contains breakouts of blood testing and blood typing markets, including a breakout by disease tested for. The report also contains estimates of several categories of blood products and profiles companies in the market. The report is available at http://www.kaloramainformation.com/Blood-Worldwide-Products-7604203/
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.